by Gal | Jun 4, 2025 | News
By Brian Finrow and Sandeep Patel June 3, 2025 Finrow is CEO and co-founder of Lumen Bioscience. Patel is an independent consultant and, during the height of the Covid-19 pandemic, was the director of BARDA Division of Research, Innovation, and Ventures (DRIVe)....
by Gal | Jun 4, 2025 | News
Spirulina, also known as blue-green algae, is edible. It can be engineered to cost-effectively produce biologics that can be taken orally. Though people have long sought to do this, Lumen Bioscience has developed platform technology that solved the various challenges...
by Gal | May 30, 2025 | News
When Clay and Marie Wilkes donated $20 million to found the Wilkes Center for Climate Science & Policy at the University of Utah in 2022, they envisioned a venture to support cutting-edge science, education, public policy and entrepreneurial solutions that...
by Gal | May 26, 2025 | News
May 23, 2025 By John Parkinson PAUL FEUERSTADT, MD, FACG, AGAF’ Paul Feuerstadt, MD, discuses the treatment’s overall safety and efficacy profile and provides insights on data around smaller subsets of patients with comorbidities. Fecal microbiota, live-jslm...
by Kole Krieger | Apr 3, 2025 | News
Full Article Here Today, Lumen Bioscience reported that its investigational oral biologic, LMN-201, achieved a 100% clinical cure rate of C difficile infection (CDI) in the sentinel cohort (Part A) of its RePreve clinical trial. All patients (21/21; 95% confidence...
4 ideas to kick-start U.S. drug research — and beat China in biotech
Revolutionizing the Production of Biologics with Algae
Past Wilkes Prize winners accelerate audacious climate solutions
Reviewing Real-World Safety and Efficacy Data on C difficile Therapy Rebyota